MOTS-c in Adolescents: Why Adult Evidence Cannot Be Assumed

Pediatric Evidence Needs a Bridge, Not a Smaller Number

The legacy page converted general caution into candidate criteria, weight-based dose ideas, laboratory schedules, school and sports monitoring, and rules for pausing treatment. No adolescent MOTS-c exposure study supported those instructions.

The International Council for Harmonisation describes the endpoint of pediatric extrapolation this way:

“The results should be submitted to support a pediatric risk-benefit assessment.”

The issuer is the ICH E11A Expert Working Group in Pediatric Extrapolation. The sentence appears in the guideline's pediatric extrapolation concept section. It states an evidence-development standard; it does not endorse MOTS-c or provide a pediatric regimen.

The Pediatric Bridge Audit

Every rung is missing or unresolved. That means adult weight, body size, or a mouse dose cannot be converted responsibly into an adolescent schedule.

What the Current Trial Can and Cannot Tell Us

NCT07505745 is a recruiting Phase 2a study in adults ages 18 to 65 with prediabetes and overweight or obesity. Its public record lists no results.

That record does not provide:

• any participant younger than 18;
• adolescent pharmacokinetics;
• effects on linear growth or pubertal development;
• neurodevelopmental or school-function outcomes;
• reproductive-development data;
• a pediatric dose; or
• a pediatric adverse-event rate.

An eligibility boundary is not an evidence bridge. Even completed adult results would need to be assessed for relevance to a specific pediatric disease and population.

Preclinical Metabolism Is Not Adolescent Safety

The foundational 2015 study identified MOTS-c biology in cells and mice and reported metabolic effects in mouse models (PMID 25738459; PMCID PMC4350682). Those experiments are important for mechanism and hypothesis generation.

They do not measure what administered MOTS-c does during human puberty. A developing person is not an adult scaled by kilograms, and a mouse outcome cannot resolve human growth, maturation, fertility, mood, or long-term immune effects.

Developmental Toxicology Is Also Missing

FDA's July 2026 review found no human exposure data for MOTS-c by any route and no clinical pharmacokinetic studies. It also found no developmental or reproductive toxicity study sufficient to answer pediatric-development questions.

That evidence gap does not prove a particular harm. It prevents a claim that those harms have been excluded.

The same distinction applies to product risk. Potential aggregation, peptide impurities, and injection-related immunogenicity concern the administered product; they do not become acceptable merely because a proposed amount is lower.

What Can Be Said Without Inventing a Protocol

The geriatric evidence audit shows the same representation problem at the other end of the age range. The older-adult dosing review explains why an adjustment cannot be calculated without a validated starting dose, and the rare-event review explains why missing human exposure prevents incidence estimates.

For adolescents, the responsible conclusion is narrower than the legacy protocol: no administered-human evidence establishes safety, benefit, dose, laboratory cadence, or a development-monitoring schedule.

Medical review of this revision is pending. ICH, FDA, trial investigators, institutions, and study authors do not endorse MOTS-c, HealthRX.com, or this page.